Back to Newsroom

BIND Therapeutics’ Presentations at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics

CAMBRIDGE, Mass.–(BUSINESS WIRE)– BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced that four abstracts have been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, November 5-9, 2015. The abstracts were published today on the AACR website at

Click here to read more